Methods for measuring serum activity levels of the 192 Q and R isoenzymes of paraoxonase 1 in QR heterozygous individuals

Clinical Chemistry

Volumn 59, Issue 8, 2013, Pages 1251-1259

  Teiber, John F ^a   Kramer, Gerald L ^a   Haley, Robert W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GENOMIC DNA; ORGANOPHOSPHATE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ATHEROSCLEROSIS; CLINICAL CHEMISTRY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYDROLYSIS; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; SERUM;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; FEMALE; HETEROZYGOTE; HUMANS; HYDROLYSIS; ISOENZYMES; MALE; MIDDLE AGED; PHENOTYPE;

EID: 84880859185     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.199331     Document Type: Article

References (28)

1. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46:1239-47.
2. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004;369:78-88.
3. Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, et al. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 2005; 26:651-9.
4. Engel SM, Wetmur J, Chen J, Zhu C, Barr DB, Canfield RL, Wolff MS. Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood. Environ Health Perspect 2011;119:1182-8.
5. Hofmann JN, Keifer MC, Furlong CE, De Roos AJ, Farin FM, Fenske RA, et al. Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect 2009;117:1402-8.
6. Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, Lapinski RH, Godbold JH, et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect 2004;112:388-91.
7. Harley KG, Huen K, Schall RA, Holland NT, Bradman A, Barr DB, Eskenazi B. Association of organophosphate pesticide exposure and paraoxonase with birth outcome in Mexican-American women. PLoS One 2011;6:e23923.
8. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009;35:98-104.
9. Connelly PW, Draganov D, Maguire GF. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic Biol Med 2005;38:164-74.
10. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371-92.
11. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-42.
12. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, et al. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 2005;15:589-98.
13. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006; 47:2492-502.
14. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95.
15. Povey AC. Gene-environmental interactions and organophosphate toxicity. Toxicology 2010;278: 294-304.
16. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337-44.
17. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 2010;660:29-35.
18. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29:566-9.
19. Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999;157:227-33.
20. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999;9:745-53.
21. Iannacchione VG, Dever JA, Bann CM, Considine KA, Creel D, Carson CP, et al. Validation of a research case definition of Gulf War illness in the 1991 US military population. Neuroepidemiology 2011;37:129-40.
22. Haley RW, Charuvastra E, Shell WE, Buhner DM, Marshall WW, Biggs MM, et al. Cholinergic autonomic dysfunction in veterans with Gulf War illness: confirmation in a population-based sample. JAMA Neurol 2013;70:191-200.
23. Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003;13:291-5.
24. Parker-Katiraee L, Bousiaki E, Monk D, Moore GE, Nakabayashi K, Scherer SW. Dynamic variation in allele-specific gene expression of paraoxonase-1 in murine and human tissues. Hum Mol Genet 2008;17:3263-70.
25. Nguyen SD, Kim JR, Kim MR, Jung TS, Soka DE. Copper ions and hypochlorite are mainly responsible for oxidative inactivation of paraoxonhydrolyzing activity in human high density lipoprotein. Toxicol Lett 2004;147:201-8.
26. Kuo CL, La Du BN. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos 1998; 26:653-60.
27. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
28. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.